Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Johns, Matthew C ^a   Eick, Angelia A ^b   Blazes, David L ^a   Lee, Seung Eun ^b   Perdue, Christopher L ^a   Lipnick, Robert ^a   Vest, Kelly G ^a   Russell, Kevin L ^a   DeFraites, Robert F ^a   Sanchez, Jose L ^a  

^a Armed Forces Health Surveillance Center   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

ADULT; AGE DISTRIBUTION; ARMY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFICACY; EPIDEMIC; FEMALE; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; SEX RATIO; UNITED STATES; VIRUS DIAGNOSIS; CASE CONTROL STUDY; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; RISK; SEASON; SOLDIER;

TIPULA IRIDESCENT VIRUS;

ADULT; AGE DISTRIBUTION; CASE-CONTROL STUDIES; DISEASE OUTBREAKS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MILITARY PERSONNEL; ODDS RATIO; SEASONS; UNITED STATES; YOUNG ADULT;

EID: 77956282644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010722     Document Type: Article

References (55)

1. Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC (1999) Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis 5: 379-385.
2. Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ (2006) Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev 28: 3-26.
3. Gaydos JC, Top FH, Jr., Hodder RA, Russell PK (2006) Swine influenza a outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis 12: 23-28.
4. WHO (2009) Ad hoc Policy Advisory Working Group on Influenza A (H1N1) vaccines. Geneva: World Health Organization.
5. WHO (2009) Summary report of a High-Level Consultation: new influenza A (H1N1). Geneva: World Health Organization.
6. Eick AA, Wang Z, Hughes H, Ford SM, Tobler SK (2009) Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 27: 3568-3575.
7. Wang Z, Tobler S, Roayaei J, Eick A (2009) Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 301: 945-953.
8. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, et al. (2009) Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 361: 1260-1267.
9. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, et al. (2008) Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 198: 312-317.
10. Rubertone MV, Brundage JF (2002) The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 92: 1900-1904.
11. AFHSC (2009) Tri-service Reportable Events: Guidelines & Case Definitions, June 2009. Armed Forces Health Surveillance Center. Available: http://www.afhsc.mil/viewDocument?file=TriService_CaseDefDocs/June09TriServGuide.pdf. Accessed 2010 April 5.
12. Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, et al. (1985) Field evaluation of vaccine efficacy. Bull World Health Organ 63: 1055-1068.
13. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, Grajales-Muniz C, Robles-Perez E, et al. (2009) Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374: 2072-2079.
14. Garcia-Garcia L, Valdespino-Gomez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, et al. (2009) Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: casecontrol study in Mexico City. BMJ 339: b3928.
15. Loeb M, Earn DJ, Smieja M, Webby R (2010) Pandemic (H1N1) 2009 risk for nurses after trivalent vaccination. Emerg Infect Dis 16: 719-720.
16. Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, et al. (2010) 2009 Influenza A (H1N1) Seroconversion Rates and Risk Factors Among Distinct Adult Cohorts in Singapore. JAMA 303; 14: 1383-1389.
17. Kelly H, Grant K (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14.
18. CDC (2009) Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. Morb Mortal Wkly Rep 58: 1241-1245.
19. Iuliano AD, Reed C, Guh A, Desai M, Dee DL, et al. (2009) Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis 49: 1811-1820.
20. Lessler J, Reich NG, Cummings DA, Nair HP, Jordan HT, et al. (2009) Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med 361: 2628-2636.
21. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, et al. (2010) Association between the 2008-09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring-Summer 2009; Four Observational Studies from Canada. PloS Med 7: e1000258. doi:1000210.1001371/ journal.pmed.1000258.
22. CDC (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. Morb Mortal Wkly Rep 58: 521-524.
23. CDC (2009) Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58: 1-8.
24. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952.
25. Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R (2003) Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 22: 28-34.
26. Block SL, Reisinger KS, Hultquist M, Walker RE (2007) Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 51: 4001-4008.
27. Russell K (2006) Respiratory infections in military recruits. In: MK L, DE L, RB NJ, eds. Textbooks of Military Medicine: Recruit Medicine. Washington, D.C.: Borden Institute. pp 227-253.
28. Cohen J (2010) What's Old Is New: 1918 Virus Matches 2009 H1N1 Strain. Science 327: 1563-1564.
29. Xu R, Ekiert DC, Krause JC, HaiRong, Crowe JE, et al. (2010) Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. Science 328: 357-360.
30. Epstein SL (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49-53.
31. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, et al. (2008) Crosssubtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 14: 121-128.
32. Goy K, Von Bibra S, Lewis J, Laurie K, Barr I, et al. (2008) Heterosubtypic Tcell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza. Influenza Other Respi Viruses 2: 115-125.
33. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic Tlymphocyte populations directed to human influenza A virus. J Virol 82: 5161-5166.
34. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478-3490.
35. Roti M, Yang J, Berger D, Huston L, James EA, et al. (2008) Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 180: 1758-1768.
36. Gerhard W (2001) The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260: 171-190.
37. Martinez O, Tsibane T, Basler CF (2009) Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol 28: 69-92.
38. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
39. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, et al. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455: 532-536.
40. Boon AC, de Mutsert G, van Baarle D, Smith DJ, Lapedes AS, et al. (2004) Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 172: 2453-2460.
41. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, et al. (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176: 6333-6339.
42. Xing Z, Cardona CJ (2009) Preexisting immunity to pandemic (H1N1) 2009. Emerg Infect Dis 15: 1847-1849.
43. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Preexisting immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106: 20365-20370.
44. Gualano RC, Hansen MJ, Vlahos R, Jones JE, Park-Jones RA, et al. (2008) Cigarette smoke worsens lung inflammation and impairs resolution of influenza infection in mice. Respir Res 9: 53.
45. Almirall J, Bolibar I, Serra-Prat M, Roig J, Hospital I, et al. (2008) New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31: 1274-1284.
46. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, et al. (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April- June 2009. N Engl J Med 361: 1935-1944.
47. Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, et al. (1992) Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 136: 296-307.
48. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E (2007) Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357: 1373-1381.
49. Nichol KL, Wuorenma J, von Sternberg T (1998) Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158: 1769-1776.
50. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35: 337-344.
51. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, et al. (2007) Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 36: 623-631.
52. CDC (2010) Advisory Committee on Immunization Practices-Provisional Recommendation for the Use of Influenza Vaccines, 2 March 2010. Atlanta: Centers for Disease Control and Prevention, Available: http://www.cdc.gov/vaccines/recs/provisional/downloads/flu-vac-mar-2010-508.pdf. Accessed: 2010 April 7.
53. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, et al. (2009) Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 199: 168-179.
54. Skowronski DM, Tweed SA, De Serres G (2008) Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 197: 490-502.
55. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, et al. (2008) Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 168: 2405-2414.